Abstract
Pharmacogenomics explores the contribution of genetics to drug safety and specifically examines the single gene interactions with drugs. It also makes use of genetic tests to distinguish among patients whose genetic characteristics predispose them to respond in certain ways to certain medicines. An understanding of the genetic variables that influence drug response could also help pharmaceutical companies design new, more effective therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bellver Capella, V., 2002, Ethics, politics, and rights in pharmacogenomics. Law Hum Genome Rev 17:31–55.
Blake, C.A., Sobel, B.E., 2008, Progress in pharmacogenomics and its promise for medicine. Exp Biol Med 233:1482–1483.
Cariou, A., Chiche, J.D., Charpentier, J., Dhainaut, J.F., Mira, J.P., 2002, The era of genomics: impact on sepsis clinical trial design. Crit Care Med 5:341–348.
Dan, M., Roden, M.D., Russ, B., et al., 2006, Pharmacogenomics: challenges and Opportunities. Annals of Internal Medicine 145(10):749–757.
Eichelbaum, M., Ingelman-Sundberg, M., Evans, W.E., 2006, Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–137.
Evans, W.E., Relling, M.V., 1999, Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491.
Gupta, M., Kaur, H., Grover, S., Kukreti, R., 2008, Pharmacogenomics and treatment for dementia induced by Alzheimer’s disease. Pharmacogenomics 9:895–903.
Johnson, J.A., 2001, Drug target pharmacogenomics: an overview. Am J Pharmacogenomics 1:271–281.
Johnson, J.A., Evans, W.E., 2001, Pharmacogenomics: the inherited basis for inter-individual differences in drug response. Annu Rev Genomics Hum Genet 2:9–39.
Johnson, J.A., Evans, W.E., 2002, Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends Mol Med 8:300–305.
Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., Brockmöller, J., 2005, Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44:1209–1225.
Kirchheiner, J., Seeringer, A., 2007, Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 1770:489–494.
Kirchheiner, J., Seeringer, A., Brockmöller, J., 2006, State of the art of pharmacogenetic diagnostics in drug therapy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49:995–1003.
Krynetski, E.Y., Evans, W.E., 1998, Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 63:11–16.
Lazarou, J., Pomeranz, B.H., Corey, P.N., 1998, Incidence of adverse drug reactions in hospitalized patients. JAMA 279:1200–1205.
Lee, S.S., 2009, Pharmacogenomics and the challenge of health disparities. Public Health Genomics 2:170–179.
López-López, M., Guerrero-Camacho, J.L., Familiar-López, I.M., 2004, Pharmacogenomics: the quest for individualized therapy. Rev Neurol 39:1063–1071.
Mancinelli, L., Cronin, M., Sadee, W., 2000, Pharmacogenomics: The promise of personalized medicine. AAPS Pharm Sci 2:4.
Moldrup, C., 2001, Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet 4:204–214.
Phillips, K.A., Veenstra, D.L., Oren, E., Lee, J.K., Sadee, W., 2001, The potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286:2270–2279.
Phillips, K.A., Veenstra, D., Sadee, W., 2000, Implications of the genetic revolution for health services research: Pharmacogenomics and improvements in drug therapy. Health Serv Res 35:128–140.
Roden, D.M., Altman, R.B., Benowitz, N.L., Flockhart, D.A., Giacomini, K.M., Johnson, J.A., Krauss, R.M., McLeod, H.L., Ratain, M.J., Relling, M.V., Ring, H.Z., Shuldiner, A.R., Weinshilboum, R.M., Weiss, S.T. Pharmacogenetics Research Network, 2006, Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749–757.
Sadee, W., 1999, Pharmacogenomics. Brit Med J 319:1286.
Sadee, W., 2002, Pharmacogenomics: The Implementation Phase. AAPS Pharm Sci 4:611–614.
Shai, R.M., Reichardt, J.K., Chen, T.C., 2008, Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 4:525–534.
Shi, J., Chen, S., 2002, Pharmacogenomics genomics approaches to optimizing drug therapy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19:156–158.
Terra, S.G., Johnson, J.A., 2002, Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward. Am J Cardiovasc Drugs 2:287–296.
Tolle, R., 2001, Information technology tools for efficient SNP studies. Am J Pharmacogenomics 1:303–314.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Debnath, M., Prasad, G.B., Bisen, P.S. (2010). Pharmacogenomics. In: Molecular Diagnostics: Promises and Possibilities. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3261-4_26
Download citation
DOI: https://doi.org/10.1007/978-90-481-3261-4_26
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3260-7
Online ISBN: 978-90-481-3261-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)